AcelRx Pharmaceuticals Statistics Share Statistics AcelRx Pharmaceuticals has 16.95M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 16.95M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 12.03M Failed to Deliver (FTD) Shares 32 FTD / Avg. Volume 0.02%
Short Selling Information The latest short interest is 393.34K, so 0% of the outstanding
shares have been sold short.
Short Interest 393.34K Short % of Shares Out n/a Short % of Float 2.6% Short Ratio (days to cover) 2.13
Valuation Ratios The PE ratio is -1.15 and the forward
PE ratio is null.
AcelRx Pharmaceuticals's PEG ratio is
0.
PE Ratio -1.15 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 1.86 P/FCF Ratio -1.17 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for AcelRx Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.56,
with a Debt / Equity ratio of 0.
Current Ratio 3.56 Quick Ratio 3.56 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 38.71
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-684.42K Employee Count 19 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -6.72% in the
last 52 weeks. The beta is 0.52, so AcelRx Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.52 52-Week Price Change -6.72% 50-Day Moving Average 0.83 200-Day Moving Average 0.84 Relative Strength Index (RSI) 49.79 Average Volume (20 Days) 138,824
Income Statement
Revenue n/a Gross Profit n/a Operating Income -15.25M Net Income -13M EBITDA -15.25M EBIT n/a Earnings Per Share (EPS) -0.87
Full Income Statement Balance Sheet The company has 8.86M in cash and 0 in
debt, giving a net cash position of 8.86M.
Cash & Cash Equivalents 8.86M Total Debt n/a Net Cash n/a Retained Earnings -457.23M Total Assets 14.99M Working Capital 4.19M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -12.68M
and capital expenditures 0, giving a free cash flow of -12.68M.
Operating Cash Flow -12.68M Capital Expenditures n/a Free Cash Flow -12.68M FCF Per Share -0.78
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ACRX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for ACRX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Oct 26, 2022. It was a
backward
split with a ratio of 1:20.
Last Split Date Oct 26, 2022 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -45.92 Piotroski F-Score 2
